<DOC>
	<DOC>NCT01295099</DOC>
	<brief_summary>To clarify the mechanisms of Keloid scar formation. Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment Identify the genetic link with Keloid scar formation. Quantify the psychological/social impact in keloid scarring patients</brief_summary>
	<brief_title>Keloid Scarring: Treatment and Pathophysiology</brief_title>
	<detailed_description />
	<mesh_term>Keloid</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Adult ( &gt; 18 years old). Keloid scarring present. Able to understand and give informed consent. Patients giving informed consent to donate keloidal or nonaffected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty). Patients with a strong familial pedigree of keloid scar formation. Open wound at or proximity of the lesion Infected lesion Pregnant or planning pregnancy in the near future Lactating (Breast Feeding) Abnormal renal or liver function tests Atrophic scars Patient under 18 years of age Immunocompromised OR immunosuppressed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>scar formation</keyword>
	<keyword>5-FU</keyword>
	<keyword>genetic link</keyword>
	<keyword>psychological impact</keyword>
	<keyword>social impact</keyword>
</DOC>